FDA Greenlights Veppanu, the First PROTAC Cancer Drug, for ESR1-Mutated Breast Cancer

Level 3 — Intermediate

The U.S. Food and Drug Administration approved Pfizer and Arvinas's vepdegestrant — sold as Veppanu — on 1 May 2026, a month ahead of the agency's planned 5 June action date. It is the first proteolysis-targeting chimera, or PROTAC, ever cleared by the FDA, and a long-promised proof of concept for a new modality in drug design.

Whereas conventional small molecules inhibit harmful proteins, PROTACs hijack the cell's own protein-disposal machinery: a bifunctional molecule binds the target on one end and an E3 ubiquitin ligase on the other, marking the target for destruction by the proteasome. The result, in principle, is more durable suppression of disease-driving proteins, including some long considered 'undruggable'.

Veppanu is indicated for adults with ER-positive, HER2-negative advanced or metastatic breast cancer harbouring an ESR1 mutation, after at least one prior line of endocrine therapy. In the pivotal VERITAC-2 trial, the drug reduced the risk of disease progression or death by 43% versus fulvestrant in ESR1-mutated patients, with median progression-free survival of 5.0 months versus 2.1 months.

The data set was mixed. Vepdegestrant failed to improve progression-free survival in the overall trial population, which included patients without the ESR1 mutation, leading the FDA to confine the label to the mutated subgroup. Pfizer and Arvinas have since transferred U.S. commercial rights to Rigel Pharmaceuticals, a San Francisco-based biotech.

modality: a particular method or type of treatment

small molecule: a chemical compound small enough to enter cells easily

ubiquitin ligase: an enzyme that marks proteins for cellular disposal

proteasome: the cellular machine that breaks down marked proteins

metastatic: having spread to other parts of the body

mutation: a change in a DNA sequence

pivotal trial: a major clinical study used to support drug approval

label: the official approved use printed on a medicine package

Level 4 — Advanced

The Food and Drug Administration's approval of vepdegestrant — branded Veppanu by sponsors Pfizer and Arvinas — on 1 May 2026 marks the first regulatory endorsement of a proteolysis-targeting chimera, a class of bifunctional small molecules that has occupied centre stage in oncology drug discovery for the better part of a decade. The decision arrived a month ahead of its scheduled PDUFA date and constitutes a validating moment for an entire modality.

Mechanistically, vepdegestrant is an oral, once-daily heterobivalent ligand that recruits the cereblon E3 ubiquitin ligase to estrogen receptor alpha, thereby targeting the receptor — particularly its ligand-binding-domain ESR1 mutants — for proteasomal degradation. The approach contrasts with selective estrogen receptor degraders such as fulvestrant, which prevent receptor activity but degrade the receptor less efficiently and require intramuscular dosing.

Approval rests on the VERITAC-2 phase-3 trial, in which vepdegestrant nearly tripled median progression-free survival in ESR1-mutated patients (5.0 months versus 2.1 months on fulvestrant) and lowered the hazard ratio for progression or death to 0.57. The drug, however, failed to outperform fulvestrant in the trial's intent-to-treat population, which included ESR1 wild-type patients — a result that prompted the FDA to restrict the label to the mutated subgroup, in line with the agency's recent emphasis on biomarker-defined indications.

Commercially, Pfizer and Arvinas have already divested U.S. rights to Rigel Pharmaceuticals, a redeployment that allows both originator companies to redirect resources toward their wider PROTAC pipelines while a specialty marketer optimises uptake. Scientifically, the green light unlocks a queue of degrader programmes targeting androgen receptor, BTK, BRD9 and IRAK4, several of which now look likely to enter pivotal trials before year-end.

PDUFA date: the FDA's target date for completing a drug review under user-fee rules

heterobivalent ligand: a molecule with two different binding ends linked together

cereblon: an E3 ubiquitin ligase frequently hijacked by PROTAC drugs

estrogen receptor alpha: a nuclear receptor whose signalling drives many breast cancers

proteasomal degradation: the breakdown of marked proteins by the proteasome

intent-to-treat population: all randomised patients analysed regardless of treatment received

hazard ratio: a measure comparing event rates between two treatment groups

biomarker-defined indication: approval limited to patients carrying a specific biological marker

Level 1 — Absolute Beginner

Level 2 — Elementary

Level 3 — Intermediate

Level 4 — Advanced

FDA Greenlights Veppanu, the First PROTAC Cancer Drug, for ESR1-Mutated Breast Cancer

Multiple Choice

True or False

Fill in the Blank